A Phase 3 interventional study of Odanacatib and Alendronate in Osteoporosis and Postmenopausal Osteoporosis, sponsored by Merck Sharp & Dohme LLC. Withdrawn. Open to female participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2015-08-27.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the therapeutic effects and safety of odanacatib on bone mineral density in osteoporotic postmenopausal women who were previously treated with alendronate.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,169 studies on the registry; 134 are open to participants now.
Of its 505 completed or terminated interventional studies of FDA-regulated products, 372 (74%) have results posted.
Compared within Osteoporosis, Postmenopausal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoporosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
(within the last year) of drug or alcohol abuse or dependence
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Odanacatib · Dietary Supplement: Cholecalciferol (Vitamin D3) · Dietary Supplement: Calcium carbonate · Other: Placebo (alendronate)
Drug: Alendronate · Other: Placebo (odanacatib) · Dietary Supplement: Cholecalciferol (Vitamin D3) · Dietary Supplement: Calcium carbonate
Odanacatib 50 mg compressed tablet will be administered orally, once-a-week, for 24 months
Also known as: MK-0822
Alendronate 70 mg compressed tablets will be administered orally, once-a-week, for 24 months; and a reduced dose of 35 mg will be administered in the same fashion to a subset of women, Japanese participants only, for the same 24-month duration.
Also known as: Alendronate Sodium, Fosamax
One compressed tablet administered orally, once-a-week, for 24 months.
Two (2) 2800 IU compressed tablets administered orally, once-a-week, for 24 months.
Dietary and supplemental sources, taken as needed, to ensure a total daily calcium intake of approximately 1200 mg.
One compressed tablet administered orally, once-a-week, for 24 months.
Percent Change from Baseline in Bone Mineral Density (BMD) of the Femoral Neck
Time frame: Baseline and Month 24
Percent Change from Baseline in BMD of the Lumbar Spine, Total Hip, and Trochanter
Time frame: Baseline and Month 24
No study locations are listed for this record.
The record gives a start of May 2012, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Odanacatib
Osteoporosis, Postmenopausal →